USANA Health Sciences, Inc. announced financial results for its fiscal fourth quarter and full year ended December 31, 2022.
Key Financial & Operating Results
Fourth quarter net sales were $228 million versus $267 million during the prior-year period.
Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021.
Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021.
Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021.
Fiscal year 2022 operating cash flow totaled $104 million.
Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 million and $2.35 to $3.30, respectively.
“Our fourth quarter and full year results were largely in line with our preliminary results announced on January 5, 2023,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“During the fourth quarter, total Active Customer counts stabilized in several key markets and increased 3% sequentially. In addition, sales and customer activity in mainland China increased during the final two weeks of the year following the Chinese government’s unanticipated shift in COVID policy. This increase in sales and customer activity was due largely to increased demand for several of our health products in China.”
“While 2022